Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03791086
Other study ID # 2017RC11
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2019
Est. completion date February 1, 2027

Study information

Verified date March 2023
Source University of Dundee
Contact James D Chalmers, MD, PhD
Phone 01382660111
Email james.chalmers@nhs.scot
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Bronchiectasis is a complex heterogeneous disorder. Treatment is challenging and many recent randomized controlled trials have been negative. It is believed that bronchiectasis as a broad diagnosis incorporates multiple different patient subgroups (also known as phenotypes) and molecular entities (referred to as endotypes). This study aims to phenotype and endotype bronchiectasis during stable disease and exacerbations, to develop strategies for personalised medicine. Primary Objective To determine molecular endotypes of bronchiectasis which can guide response to treatment. Secondary Objectives 1. To determine molecular endotypes of stable bronchiectasis 2. To determine the causes and inflammatory profiles of bronchiectasis exacerbations 3. To validate candidate biomarkers of stable and exacerbation endotypes to use in stratified medicine 4. To perform in-vivo or in-vitro proof of concept studies using phenotypic data to identify patient populations likely to benefit in future randomized controlled trials This is an observational cohort study that will aim to identify patient subgroups and link these with meaningful clinical outcomes.


Description:

Background: Bronchiectasis is a common disabling and heterogeneous disease that has been neglected in terms of basic and clinical research. Recent controlled trials have failed to achieve their primary end-points, likely because the optimal patient population to benefit from antibiotic, mucoactive and anti-inflammatory drugs has not been identified. This study aims to explore the clinical, microbiological, inflammatory and functional heterogeneity of the disease with the aim of identifying patient endotypes for stratified medicine. Study aims and objectives 1. To determine the molecular endotypes of bronchiectasis during stable disease 2. To determine the causes and inflammatory profiles of bronchiectasis exacerbations 3. To validate candidate biomarkers of stable and exacerbation endotypes to use in stratified medicine 4. To perform in-vivo or in-vitro proof of concept studies using phenotypic data to identify patient populations likely to benefit in future randomized controlled trials Study Design: Observational Cohort study Study methods: Patients with bronchiectasis will be recruited into an observational study, the objectives of which will be to: Aim 1 will define and validate endotypes of stable bronchiectasis by studying up to 1000 patients with bronchiectasis. Clinical data, sputum microbiome, sputum proteomics, and systemic and sputum inflammatory marker measurement will be incorporated for analysis. A sub-study (n=200) will be performed using air liquid interface culture of primary airway epithelial cells. Patients will have brushings of the inferior nasal turbinate with assessment of % ciliation, ciliary beat frequency and pattern by high speed video microscopy before and after culture. Aim 2 will replicate the phenotyping approach to stable patients with 160 patients during exacerbation. This will identify changes from baseline in microbiota, proteomic and other markers associated with onset of exacerbation and allow classification of clusters of exacerbation. Aim 3, we will externally validate candidate phenotype/endotypes in registered ethically approved external biobanks and aim to demonstrate that validated markers to be linked to potential treatment responses for use in stratified medicine trials. In total we will recruit 1000 patients for study. These patients will attend the Clinical Research Centre at one of the participating study centres at least once and undergo sampling along with collecting of clinical data. Patients will be asked to consent for their samples to be linked to data held on the EMBARC registry. Nature of outputs and outcomes/results expected: This study will aim to establish detailed endotypes in bronchiectasis which can guide response to treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date February 1, 2027
Est. primary completion date February 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - A previous CT scan showing bronchiectasis along with compatible clinical syndrome of cough, sputum production and/or recurrent respiratory tract infections. - A primary diagnosis of bronchiectasis made by a respiratory physician - At the screening visit the individual will have been clinically stable for 4 weeks indicated by the lack of any treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks. Exclusion Criteria: - Inability to give informed consent - <18years of age - Patients with active tuberculosis - Treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks - Bronchiectasis due to cystic fibrosis

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom University of Dundee Dundee

Sponsors (1)

Lead Sponsor Collaborator
University of Dundee

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of exacerbations Worsening of respiratory symptoms as defined by the EMBARC/BRR definition- Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. up to 3 years
Secondary Time to first exacerbation Time to first event after enrolment as defined by the EMBARC/BRR definition- Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. 3 years
Secondary Quality of life- the quality of life bronchiectasis questionnaire (QOL-B) Validated questionnaire 3 years
Secondary Quality of life- the St Georges Respiratory Questionnaire (SGRQ) Validated questionnaire 3 years
Secondary Quality of life- The Bronchiectasis impact measure (BIM) Questionnaire undergoing validation 3 years
Secondary Quality of life- The Bronchiectasis Health Questionnaire (BHQ) Validated questionnaire 3 years
Secondary Forced expiratory volume in 1 second (FEV1) Spirometry 3 years
Secondary Severity of disease (the bronchiectasis severity index) Validated severity assessment tool 3 years
Secondary Hospitalisation for severe exacerbations Admission to hospital for an exacerbation meeting the EMBARC/BRR exacerbation definition 3 years
Secondary All cause mortality Survival during the study 3 years
Secondary Infection with Pseudomonas aeruginosa Defined as isolation in sputum culture or bronchoalveolar lavage meeting the criteria for chronic infection- Ann Am Thorac Soc. 2015 Nov;12(11):1602-11. 3 years
Secondary Sputum volume Measured in millilitres per day 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Recruiting NCT06093191 - Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis Phase 4
Recruiting NCT06393257 - Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis N/A
Not yet recruiting NCT04509661 - Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation Phase 4
Recruiting NCT06017739 - Expiratory Flow Accelerator (Efa) vs Efa + High Flow in Chronic COPD and Bronchiectasis N/A
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Recruiting NCT03715322 - Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa Phase 3
Recruiting NCT03696290 - Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis Phase 2
Not yet recruiting NCT05068518 - The Role of Airway Microbiota on Clinical Phenotypes and Disease Severity in Bronchiectasis
Recruiting NCT04658277 - Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations N/A
Completed NCT04744220 - Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis N/A
Completed NCT05764343 - The Effect of Immediate Smoking Cessation Interventions for Smokers With Chronic Airway Diseases N/A
Recruiting NCT05582798 - Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function Phase 4
Not yet recruiting NCT04987827 - Investigating the Clinical Features and Prognosis of Bronchiectasis Adult Patients
Completed NCT04234789 - Predictors of Physical Activity Performance and Dynamic Hyperinflation in Patients With Bronchiectasis N/A
Recruiting NCT04865861 - The Characteristic of Airway Microbiome Profiling of COPD-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
Completed NCT04742270 - Home Airway Clearance in Patients With Bronchiectasis (Home-Care Bronchiectasis) N/A
Recruiting NCT05330637 - Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.
Completed NCT05989360 - The Utility of Lung Clearance Index in Ethnic Groups and in Disease N/A
Completed NCT03125174 - Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls N/A